Recombinant Human PSMA5, N-His

Description of Recombinant Human PSMA5, N-His

Introduction:

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed in prostate cancer cells. It has been identified as a promising drug target due to its overexpression in prostate cancer and its role in tumor growth and progression. Recombinant human PSMA5, N-His is a genetically engineered form of this protein that has been widely used in research and drug development. In this article, we will explore the structure, activity, and potential applications of recombinant human PSMA5, N-His as a drug target.

Structure of Recombinant Human PSMA5, N-His:

Recombinant human PSMA5, N-His is a 100 kDa protein that is composed of 750 amino acids. It is a type II transmembrane protein, meaning that it spans the cell membrane with both its N- and C-termini located on the cytoplasmic side. The extracellular domain of PSMA5 contains a highly conserved catalytic domain, which is responsible for its enzymatic activity. The intracellular domain of PSMA5 contains a PDZ binding motif, which plays a role in protein-protein interactions.

Activity of this protein:

The main function of PSMA5 is the hydrolysis of N-acetyl-L-aspartyl-L-glutamate (NAAG), a neuropeptide that regulates glutamate signaling in the central nervous system. This activity is essential for maintaining normal glutamatergic neurotransmission and has been implicated in various neurological disorders. In prostate cancer, PSMA5 has been shown to have additional functions, such as promoting tumor growth and angiogenesis, and inhibiting apoptosis. Recombinant human PSMA5, N-His retains the same enzymatic activity as the native protein, making it a valuable tool for studying its role in disease and for developing targeted therapies.

Applications of Recombinant Human PSMA5, N-His:

Recombinant human PSMA5, N-His has been used in various applications, including drug discovery, protein-protein interaction studies, and diagnostic imaging. Due to its overexpression in prostate cancer cells, PSMA5 has been targeted for the development of novel therapies. Recombinant human PSMA5, N-His has been used in high-throughput screening assays to identify small molecule inhibitors of PSMA5 activity. These inhibitors have shown promising results in preclinical studies and are currently in clinical trials for the treatment of prostate cancer.

In addition to its role as a drug target, recombinant human PSMA5, N-His has also been utilized in protein-protein interaction studies. The PDZ binding motif in the intracellular domain of PSMA5 has been shown to interact with various proteins involved in cancer signaling pathways. Recombinant human PSMA5, N-His can be used to study these interactions and their potential as therapeutic targets.

Moreover, PSMA5 has been exploited for its potential in diagnostic imaging. Prostate-specific membrane antigen-targeted imaging agents, such as 68Ga-PSMA-11, have been developed for the detection and staging of prostate cancer. These agents have shown high sensitivity and specificity in clinical studies, making them a promising tool for early detection and monitoring of prostate cancer. Recombinant human PSMA5, N-His has been used to produce these imaging agents, further highlighting its importance in the field of cancer diagnosis and treatment.

Conclusion:

Recombinant human PSMA5, N-His is a valuable tool for understanding the structure and function of PSMA5, a promising drug target for prostate cancer. Its enzymatic activity, role in protein-protein interactions, and potential in diagnostic imaging make it a versatile protein with various applications in research and drug development. With ongoing studies and clinical trials, recombinant human PSMA5, N-His holds promise for the future of prostate cancer treatment.